Recurrence of hepatitis C infection: Where are we now?

✍ Scribed by Michael Charlton

• Book ID: 102471779
• Publisher: John Wiley and Sons
• Year: 2005
• Tongue: English
• Weight: 121 KB
• Volume: 11
• Category: Article
• ISSN: 1527-6465
• DOI: 10.1002/lt.20597

✦ Synopsis

Key

Points 1. Hepatitis C-associated liver failure is the most common indication for liver transplantation, and approximately 10% of HCV-infected recipients will die or lose their allograft secondary to recurrent HCV infection. 2. Risk factors associated with histological recurrence of HCV include donor (age, fat content, ischemic time, and living donor), recipient (age and non-Caucasian race), clinical (rejection and CMV), and viral (viral load and quasispecies). 3. Treatment of recipients with histological recurrence is with pegylated IFN (؎ ribavirin). The role of hepatitis C immunoglobulin in the management of postransplant HCV is still evolving. (Liver Transpl 2005;11:S57-S62.)

L iver disease secondary to hepatitis C (HCV) infec- tion continues to be the most common indication for liver transplantation worldwide. Although the impact of HCV infection on allograft histology varies substantially, allograft failure secondary to recurrence of HCV infection is the most common cause of death and retransplantation among recipients with HCV infection. 1 In this article, we review potential strategies for the prevention of recurrent HCV infection.